PathogenDx Receives CE-IVD Mark for Its Microarray-Based DetectX-Rv Test for COVID-19

The low-cost, high-throughput test will now be available for qualified laboratories across the European Union SCOTTSDALE, Ariz., July 21, 2021 -- (Healthcare Sales & Marketing Network) -- PathogenDx, Inc., an Arizona based biotechnology company which h... Diagnostics, Regulatory PathogenDx, COVID-19
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news